未找到相关数据
Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.
被引：0
作者：
Al-Rajabi, Raed Moh'd Taiseer
Kasi, Anup
Baranda, Joaquina Celebre
Saeed, Anwaar
Li, Haoran
Bruey, Collin
Best, Shaun
Phadnis, Milind A.
Sun, Weijing
机构：
[1] Univ Kansas, Canc Ctr, Westwood, KS USA
[2] Univ Kansas, Canc Ctr, Fairway, KS USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[4] Univ Kansas, Med Ctr, Kansas City, KS USA
[5] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, KS USA
关键词：
283-237-2581-144;
261-492-3532-2370-7650-2700;
613-225-313;
298-145-222-184-1022-9122;
261-492-2769;
281-5277-2560;
283-2494;
7;
4;
3;
2;
250;
2018;
91;
176;
62;
6;
1;
38092-18909;
38116-38094-8;
5;
D O I：
10.1200/JCO.2024.42.3_suppl.TPS581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS581
引用
收藏
页码：TPS581 / TPS581
页数：1
相关论文